Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)
Oppenheimer Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Maintains Target Price $14
RBC Capital Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating, Maintains Target Price $4
Fulcrum Therapeutics Analyst Ratings
H.C. Wainwright Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating, Maintains Target Price $4
A Quick Look at Today's Ratings for Fulcrum Therapeutics(FULC.US), With a Forecast Between $2 to $22
Hold Rating on Fulcrum Therapeutics Amid Phase 3 Drug Failure and Pivot to Sickle Cell Disease Candidate
RBC Downgrades Fulcrum Therapeutics to Sector Perform From Outperform, Cuts Price Target to $4 From $15; Speculative Risk Kept
Fulcrum Therapeutics Price Target Announced at $4.00/Share by Leerink Partners
Fulcrum Therapeutics Cut to Market Perform From Outperform by Leerink Partners
Fulcrum Therapeutics Analyst Ratings
Stifel Downgrades Fulcrum Therapeutics(FULC.US) to Hold Rating, Maintains Target Price $22
Stifel Nicolaus Keeps Their Buy Rating on Fulcrum Therapeutics (FULC)
Fulcrum Therapeutics Raised to Neutral From Underperform by B of A Securities
Fulcrum Therapeutics Analyst Ratings
BofA Securities Upgrades Fulcrum Therapeutics(FULC.US) to Hold Rating, Announces Target Price $10
RBC Capital Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Raises Target Price to $15
Stifel Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Maintains Target Price $22
Stifel Nicolaus Keeps Their Buy Rating on Fulcrum Therapeutics (FULC)
Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (ALHC), Exact Sciences (EXAS) and Fulcrum Therapeutics (FULC)